Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer

Preclinical works have suggested cytotoxic chemotherapies may increase the number of cancer stem cells (CSC) whereas angiogenesis inhibition may decrease CSC proliferation. We developed a proof of concept clinical trial to explore bevacizumab activity on breast CSC. Breast cancer patients requiring...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatier, Renaud, Charafe-Jauffret, Emmanuelle, Pierga, Jean-Yves, Curé, Hervé, Lambaudie, Eric, Genre, Dominique, Houvenaeghel, Gilles, Viens, Patrice, Ginestier, Christophe, Bertucci, François, Sfumato, Patrick, Extra, Jean-Marc, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572380/
https://www.ncbi.nlm.nih.gov/pubmed/31064127
http://dx.doi.org/10.3390/jcm8050612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572380/
https://www.ncbi.nlm.nih.gov/pubmed/31064127
http://dx.doi.org/10.3390/jcm8050612

Ejemplares similares